Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to fight hard-to-treat skin cancer

NCT ID NCT06940440

Recruiting now Disease control Sponsor: TuHURA Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 29 times

Summary

This early-stage trial tests whether adding an experimental drug, IFx-Hu2.0, to the standard immunotherapy pembrolizumab is safe and doable for people with advanced Merkel cell carcinoma that has spread. Nine adults will receive an injection of IFx-Hu2.0 directly into a tumor, followed by pembrolizumab. The goal is to see if this combination can be given without serious side effects and if it is practical to use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC MERKEL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • H. Lee Moffitt Cancer Center and Research Institute

    RECRUITING

    Tampa, Florida, 33612, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Wisconsin Carbone Cancer Center

    RECRUITING

    Madison, Wisconsin, 53792, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

ADVANCED OR METASTATIC MERKEL CELL CARCINOMA